Oric Reports Enozertinib Phase 1b Results, Plans Phase 3 in 2027
Oric reported systemic and intracranial activity for enozertinib in Phase 1b and plans a global Phase 3 trial in the first half of 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.